J&J appoints Dr John Reed as EVP, Pharma, R&D
Dr Reed will join J&J on April 3, 2023, assuming responsibility for the company’s portfolio from Dr William Hait, who has served as interim head of J&J’s pharma R&D organisation since August 2022
Johnson & Johnson (J&J) announced the appointment of Dr John Reed to the company’s Executive Committee as Executive VP of Pharmaceuticals, R&D. Dr Reed previously served as Executive VP, Global Head of Research and Development for Sanofi and brings more than 35 years of biomedical research leadership to the company.
Dr Reed will join J&J on April 3, 2023, assuming responsibility for the company’s industry-leading portfolio from Dr William Hait, who has served as interim head of J&J’s pharma R&D organisation since August 2022.
Joaquin Duato, Chairman of the Board and CEO of J&J commented, “Dr Reed is an accomplished leader and highly regarded researcher with an extraordinary track record for discovering and developing life-saving innovations on a global scale. I am confident his experience and leadership will enable our pharma R&D organisation to continue to accelerate innovation and competitiveness, invest with focus and discipline and improve the lives of the patients we serve around the world with transformational medicines.”
Dr Reed said, “I am deeply honoured and extremely excited to join J&J. I share the company’s commitment to innovation to conquer disease and improve human health, and I look forward to applying my passion for science, experience in drug discovery and development and commitment to helping patients in leading the talented pharma R&D team.”